Two Sigma Investments, LP Contrafect Corp Transaction History

Two Sigma Investments, LP

  • $42.3 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.09 - $0.19 $4,059 - $8,569
-45,100 Reduced 19.39%
187,551 $18,000
Q3 2022

Nov 14, 2022
BUY
$0.18 - $3.51 $41,877 - $816,605
232,651 New
232,651 $39,000
Q3 2021

Nov 15, 2021
SELL
$3.19 - $4.43 $78,793 - $109,421
-24,700 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$3.58 - $4.9 $88,426 - $121,030
24,700 New
24,700 $109,000
Q4 2020

Feb 16, 2021
SELL
$5.05 - $6.4 $111,771 - $141,651
-22,133 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$5.05 - $6.99 $111,771 - $154,709
22,133 New
22,133 $117,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email